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Abstract
Background: Multiple sclerosis is a chronic inflammatory, demyelinating disease of the central nervous system.
Recent genome-wide studies have revealed more than 110 single nucleotide polymorphisms as associated with
susceptibility to multiple sclerosis, but their functional contribution to disease development is mostly unknown.
Results: Consistent allelic imbalance was observed for rs907091 in IKZF3 and rs11609 in IQGAP1, which are in strong
linkage disequilibrium with the multiple sclerosis associated single nucleotide polymorphisms rs12946510 and
rs8042861, respectively. Using multiple sclerosis patients and healthy controls heterozygous for rs907091 and
rs11609, we showed that the multiple sclerosis risk alleles at IKZF3 and IQGAP1 are expressed at higher levels as
compared to the protective allele. Furthermore, individuals homozygous for the multiple sclerosis risk allele at
IQGAP1 had a significantly higher total expression of IQGAP1 compared to individuals homozygous for the
protective allele.
Conclusions: Our data indicate a possible regulatory role for the multiple sclerosis-associated IKZF3 and IQGAP1
variants. We suggest that such cis-acting mechanisms may contribute to the multiple sclerosis association of single
nucleotide polymorphisms at IKZF3 and IQGAP1.
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Background
Multiple sclerosis (MS) is a chronic inflammatory dis-
order of the central nervous system (CNS). Hallmarks of
the disease are inflammatory demyelination and axonal
loss in the CNS, resulting in neurological dysfunction,
typically starting in early adulthood [1]. The cause of the
disease is largely unknown, but genetic and environmen-
tal factors, as well as interaction of these contribute to
disease development [2]. The strongest genetic factor in
MS, the Human Leukocyte Antigen (HLA) gene region,
was identified already in 1972 [3], and HLA-DRB1*15:01
displays the strongest genetic signal [4]. Through recent
large genome - wide association studies (GWASs)
followed up by genome-wide analyses of immune-related
loci, more than 110 non-HLA genetic variants were
shown to be associated with MS susceptibility [4, 5]. The
majority of the MS-associated single nucleotide poly-
morphisms (SNPs) identified through GWAS are located
in or near genes having a substantial role in the immune
system [4, 6].
An important aim of human genetic research is identi-
fication of heritable variation in cis-regulatory elements
for gene expression that might influence disease risk [7].
The majority (93 %) of the disease susceptibility variants
identified through large-scale genetic screens such as
GWAS and the immunochip project is located within
non-coding regions of the genome [8]. For MS, an en-
richment of disease-associated variants is observed in
DNase hypersensitive sites in immune cells, especially
for T and B cells [8, 9]. Genetic variants may therefore
have an influence on the expression of target genes, and
the MS-association of the polymorphisms identified
through the genetic screens is likely to be the result of
such regulatory properties. However, the functional im-
plications of the genetic variants associated with MS are
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largely unknown. To address this, follow-up studies of
these MS associated loci are needed to gain insights in
the underlying molecular mechanisms. Analysis to un-
ravel whether MS-associated SNPs exert cis-acting regu-
lation is now an important next step in MS research.
Such insights will contribute to improved understanding
of disease aetiology and may allow development of novel
biomarkers and therapies for MS.
The Genotype-Tissue Expression database (GTEx) is
providing a valuable tool to investigate genotype-
dependent gene regulation. The use of a great variety of
tissues from human post-mortem donors allows compar-
ing putative genotype-dependent gene regulation be-
tween at least 44 tissues in the publicly available pilot
data [10]. Data from expression quantitative trait locus
(eQTL) databases such as the GTEx is generally based
on analyses in heterogeneous groups of individuals, how-
ever in specific diseases, gene regulation may be altered
due to a disturbed homeostasis. For MS, it is proposed
that whole blood composition and immune cell activity
is different from healthy controls [11, 12]. In the current
study, we have investigated the allele - specific expres-
sion (ASE) of MS-associated SNPs or proxies thereof in
whole blood from a cohort of Norwegian MS patients.
The unequal output of gene transcript, allelic imbal-
ance (AI), has been established as a ubiquitous
phenomenon that may underlie disease risk exerted
by disease-associated SNPs [13]. AI may occur when
the SNP-containing sequence is within a cis-regula-
tory region of a gene. A prerequisite to study putative
effects on allelic output for disease associated SNPs is
that the SNP itself, or a proxy SNP on the same
haplotype as the susceptibility SNP, is transcribed.
The per-allele expression levels for a transcribed SNP
can then be determined in individuals heterozygous
for the studied SNP.
Here, we investigate three SNPs in MS associated re-
gions for the presence of AI; (i) the MS-associated SNP
rs11052877, which lies in the coding region of CD69, (ii)
the rs907091 SNP in the coding region of IKZF3 and in
strong linkage disequilibrium (LD) with the MS-
associated rs12946510 and (iii) the rs11609 SNP located
in the coding region of IQGAP1and in strong LD with
the MS-associated rs8042861. Although the data from
the GTEx database is extensive, there are examples of
genotype-expression correlations not detected. Interest-
ingly, GTEx reports no effect of rs907091 genotype on
IKZF3 expression, whereas Fahr and colleagues [14]
refer to rs907091 as an eQTL for IKZF3 in lymphoblas-
toid cell lines [15]. Furthermore, rs11609 in IQGAP1 is
reported as an eQTL for IQGAP1 in a wide variety of
tissues, but not in whole blood, whereas no SNPs are re-
ported as eQTLs for CD69 in any of the tissues (GTEx,
accessed March 2016). In the current analyses, ASE
measurements for three SNPs in these three genes
(CD69, IKZF3 and IQGAP1) were performed in whole
blood samples from Norwegian MS patients and healthy
controls.
Methods
Subjects, sample collection and reverse transcription of
RNA
Blood samples were collected for DNA (EDTA tubes,
Greiner Bio-One, Frickenhausen, Germany) and RNA
isolation (Tempus tubes, Applied Biosystems, Foster
City, CA, USA) from 140 MS patients collected in the
Norwegian multiple sclerosis registry and biobank [16]
and 46 healthy controls (14 for RNA extraction) re-
cruited among hospital employees. The MS patients are
representative of the Norwegian MS patient population
[17]. DNA isolations were performed using DNA isola-
tion columns, and RNA was extracted from Tempus
tubes with the Tempus Spin RNA Isolation Kit protocol
(Applied Biosystems), including DNase treatment during
extraction. The concentration of all DNA and RNA sam-
ples was assessed by a nanodrop 2000c spectrophotom-
eter (Thermo Fisher Scientific Inc., Madison, WI, USA).
An RNA integrity number above 7.0 of a random set of
these RNA samples was verified using the Agilent 2100
Bioanalyzer (Agilent Technologies, Santa Clara, CA,
USA). For DNA samples that were used for sensitivity
analyses of assays for ASE analyses (see below), the con-
centration was measured by Qubit Broad Range DNA
spectroscopy (Qubit, Life Technologies, Carlsbad, CA,
USA). According to manufacturers’ protocol, 200 ng
RNA was reverse transcribed (RT) with Maxima First
Strand complementary DNA (cDNA) synthesis Kit for
quantitative polymerase chain reaction (qPCR) (Thermo
Scientific, Pittsburgh PA, USA) in a 20 μl reaction.
Single nucleotide polymorphisms included for allele-
specific expression analysis
We used the online tools SNAP for identifying proxy
SNPs for the MS associated SNPs [18] and SNPper [19]
for determining which of these proxies were transcribed
for all 110 non-HLA MS-associated SNPs recently re-
ported [4, 5]. Three genes, which had a transcribed MS-
associated SNP or transcribed proxy for an MS-
associated SNP were selected for ASE analyses; CD69,
with the MS-associated SNP rs11052877 in its coding
region, and IKZF3 and IQGAP1, where rs907091 and
rs11609, respectively, are in strong LD (r2 ≥ 0.8) with
MS-associated SNPs. To verify that the SNP-containing
regions were expressed in whole blood, PCRs followed
by agarose gel electrophoresis were done on cDNA gen-
erated from whole blood. Primer sequences are provided
in Additional file 1: Table S1.
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Genotyping
Genotyping of rs11052877, rs907091, rs11609, rs12946510
and rs8042861 in DNA from the MS patients and healthy
controls included those for the Western blot analyses
(rs11609 only) was done with TaqMan genotyping as-
says (C_32169538_10, C_7452266_20, C_26774507_10,
C_31651862_10 and C_12091833_10 respectively (Ap-
plied Biosystems)). The genotyping reactions were
carried out in 5 μl using 12 ng of genomic DNA
(gDNA), 0.125 μl 40x TaqMan assay and 2.5 μl
TaqMan genotyping master mix in a MicroAmp Op-
tical 384 well reaction plate (Applied Biosystems) on
a ViiA7 Real-Time PCR system (Applied Biosystems).
Data were analysed by the sequence detection system
(SDS) v. 2.3 (Applied Biosystems). Healthy control ge-
notypes for the ASE analyses of ten of the samples
were assessed previously [20], whereas the remaining
four samples were genotyped as described above.
Sensitivity assessment of allele-specific expression
To assess the sensitivity of the allele-specific qPCR,
gDNA homozygous for either allele of the corresponding
SNPs were mixed in ratios of 4:1, 2:1, 1.5:1, 1.25:1, 1:1,
1:1.25, 1:1.5, 1:2 and 1:4. The ratios of allele-specific sig-
nals of these mixtures were quantified by real-time
qPCR using TaqMan genotyping assays in TaqMan Uni-
versal Master Mix II, without UNG (Applied Biosys-
tems), while including a heterozygous gDNA sample as
a 1:1 ratio control of the alleles (Additional file 2: Figure
S1). The samples were run in triplicate in a MicroAmp
Optical 384 well reaction plate (Applied Biosystems) on
ViiA7 Real-Time PCR system (Applied Biosystems), and
data were analysed by SDS v. 2.3 (Applied Biosystems).
Allele-specific expression
For each cDNA sample from heterozygous donors, five
replicate real-time qPCR measurements were performed
using 5.66 ng of cDNA in a 10 μl reaction additionally
containing 0.25 μl 40x Primer Probe mix (Applied Bio-
systems), 5 μl TaqMan Universal master mix II, without
UNG (Applied Biosystems) and 4.15 μl RNase-free water
(Qiagen, Hilden, Germany). Genomic DNA (50 ng) from
all heterozygous individuals was used to determine the
technical difference in signals between alleles at an equal
allele presence. The gDNA and cDNA samples were
assayed using the same genotyping TaqMan primers and
probes for the respective assays. All cDNA measure-
ments were normalized against this technical difference
(see data analyses and statistics below). Each plate in-
cluded a negative control without cDNA and a no–RT
control. The PCR reactions were performed in a Micro-
Amp optical 384 well reaction plate (Applied Biosys-
tems) on the ViiA7 Real-Time PCR system (Applied
Biosystems), and data were analysed by SDS v. 2.3 soft-
ware (Applied Biosystems).
Quantitative real-time polymerase chain reaction of
homozygous samples
For each homozygous sample, cDNA generated from
6.52 ng RNA was assayed in 10 μl final volume containing
0.5 μl of 20x Primer Probes (IKZF3: Hs00232635_m1 or
IQGAP1: Hs00896595_m1, Applied Biosystems), 5 μl Taq-
Man Gene expression Master mix (Applied Biosystems)
and 3.5 μl RNase-free water (Qiagen). A negative control
without template and no–RT control were included in
each plate. The reactions were performed in duplicates in
a MicroAmp optical 384 well reaction plate (Applied Bio-
systems) on the ViiA7 Real-Time PCR system (Applied
Biosystems), and data were analysed by SDS v. 2.3 soft-
ware (Applied Biosystems). A standard curve was pre-
pared from whole blood RNA from MS cases with a 1:2
fold dilution series (33.33-0.26 ng/μl). Gene expression
was normalized relative to the housekeeping genes 18S
rRNA (4319413E), TBP (4326322E), and GAPDH
(Hs03929097_g1). 18S rRNA was selected as the preferen-
tial reference gene given its low variance in Ct between
the different samples (data not shown).
Peripheral blood mononuclear cells collection, cell lysis
and Western blot analyses
Whole blood samples from 32 healthy donors were
collected among hospital employees and peripheral
blood mononuclear cells were isolated by Lympho-
prep (Axis Shield, Dundee, Scotland). Cells were re-
suspended in reducing SDS-loading buffer, sonicated
and heated at 95 °C for 5 min. Proteins from 250,000
cells were separated by SDS-polyacrylamide gel elec-
trophoresis using pre-made Criterion gels (BioRad,
Hercules, CA, USA) and transferred to polyvinylidene
fluoride membrane (BioRad) using a Hoefer Semi-
Phor Semi-Dry transfer unit (Amersham Biosciences,
Buckinghamshire, UK). The membrane was blocked
in 3 % skimmed milk in Tris-buffered saline (TBS,
pH 7.4) containing 0.1 % Tween-20 (Sigma Aldrich
Corp., St Louis, MO, USA) (TBS-T) before incubation
with antibodies, rabbit anti-IQGAP1 (ab133490,
Abcam, Cambridge, UK) or mouse anti-GAPDH (6C5,
sc-32233, Santa Cruz Biotechnology, Dallas, TX,
USA). Bound antibodies were visualized by incubation
with secondary horseradish peroxidase-conjugated
goat anti-rabbit IgG or goat anti-mouse IgG (Jackson
ImmunoResearch Laboratories Europe Ltd., Suffolk,
UK) and ECL prime Western blotting detection re-
agent (GE Healthcare, Oslo, Norway ) and the Chemi-
Doc Touch Imaging System (BioRad). Densiometry of
the Western blots was analysed by the ImageJ soft-
ware [21].
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Data analyses and statistics
Per donor in the ASE measurements, outlier values were
excluded after inspection of box plots using SPSS (IBM
SPSS Statistics v21.0, Chicago, IL, USA). Initially, mea-
surements with extreme values were excluded, followed
by generation of new box plots for the remaining data.
Values marked as outlier values in the newly generated
box plots were also excluded before analyses (for details
on excluded measurements, see Additional file 3: Table
S2). For each heterozygous donor, the relative allelic ex-
pression of the two alleles was expressed as delta cycle
threshold (ΔCt) = Ct (Allele2, FAM)—Ct (Allele1, VIC).
To account for technical differences between the used
fluorophores, the ΔCt was normalized to the mean ΔCt
of all gDNA (normalized ΔCt (nΔCt) =ΔCtcDNA (per sample)
-ΔCtgDNA (mean all samples)). For each assessed SNP, a two-
tailed, unpaired Student’s t-test was used to identify
significant differences of the nΔCt per sample using the
gDNA measurements grouped as the reference group. To
test for differences on a global level, a two-tailed, unpaired
Student’s t-test was performed on all cDNA pooled against
all gDNA pooled. Association between gene or protein
expression and genotype was assessed by two-sided
Mann–Whitney U-test using GraphPad Prism 6 (GraphPad




A total of 140 MS patients were available for the study,
of whom 92 were heterozygous for at least one of the
three SNPs studied; i.e. rs11052877 (CD69), rs907091
(IKZF3) and rs11609 (IQGAP1), and therefore included
in the analyses. In Table 1 we summarize the character-
istics of the patients and the healthy controls used in the
AI measurements such as the male to female ratio, age
at onset and fraction of oligoclonal band positive pa-
tients. The included patient group was representative of
the Norwegian MS patient population [17]. Treatment
data for the patients at the time of blood drawing was
not available.
Selection of single nucleotide polymorphisms for allele-
specific expression of multiple sclerosis candidate genes
From the list of 110 non-HLA MS-associated SNPs [4,
5], we selected three SNPs for ASE analyses, based on
the gene containing a transcribed SNP or suitable proxy
SNP and the possible biological role of the gene in the
immune system. The MS-associated SNP rs11052877 is
located in a transcribed region of CD69, whereas the
remaining transcribed SNPs analysed; rs907091 in IKZF3
and rs11609 in IQGAP1, are in high LD with the MS-
associated SNPs. The r2 (D’) of rs907091 to rs12946510
is 0.80 (0.90), whereas the r2 (D’) of rs11609 to
rs8042861 is 0.86 (0.93).
Consistent allelic imbalance is observed for rs907091 in
IKZF3 and rs11609 in IQGAP1
Among the 92 MS patients that were heterozygous for
at least one of the three SNPs studied, 58 patients were
heterozygous for rs11052877 (CD69), 30 patients were
heterozygous for rs907091 (IKZF3) and 61 were hetero-
zygous for rs11609 (IQGAP1). For each SNP, these sam-
ples were analysed for ASE by quantification of the
alleles in cDNA generated from whole blood.
For the rs11052877 SNP in CD69, 52 % of the samples
carrying the MS risk allele displayed lower expression of
the MS risk allele, whereas 26 % of the samples dis-
played higher expression and the remaining 22 % of the
samples displayed no significant AI (Fig. 1a). This shows
that there is no consistent cis-regulatory mechanism for
CD69 associated with this SNP. Contrary to that, the
transcript of the haplotype containing the MS risk allele
at rs907091 in IKZF3, showed consistently higher ex-
pression level in all MS samples (Fig. 1b), whereas the
transcript of the haplotype containing the MS risk allele
at rs11609 in IQGAP1 was higher in the majority (90 %)
of MS samples (Fig. 1c). For rs907091 in IKZF3, this dif-
ference corresponded to 1.17 in nΔCt value and to an
expression ratio of the MS risk allele of 2.25:1. For
rs11609 in IQGAP1, the nΔCt in the significant samples
was 0.202, which corresponds to an expression ratio of
the risk allele versus non-risk allele of 1.15:1. When we
compared all cDNA as a group against all gDNA as the
Table 1 Clinical and demographic information about the included MS patients and healthy controls
Healthy controls
MS patients ASE analyses Western blot analyses
Variable n= n= n=
Male : Female ratio 92 1 : 3.4 14 1 : 4.7 32 1 : 1.5
Age in years, mean (range) at sampling 92 50 (19–80) 14 39 (22–57) 32 37 (21–68)
Age in years, mean (range) at disease onset 89 35 (14–60)
Disease course at onset, fraction of relapsing-remitting MS 86 0.87
Oligoclonal bands, positive fraction 68 0.91
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reference group, the significant differences in AI be-
tween these two groups persisted for IKZF3 as well as
IQGAP1.
Since an incomplete LD (r2 = 0.86, D’ = 0.93) exists be-
tween the studied SNP rs11609 and the reported MS as-
sociated SNP rs8042861 [5] in IQGAP1, we analysed
whether the lack of AI for rs11609 in a small proportion
of the samples could be due to absence of the MS-risk
allele for these samples. However, all samples except one
were also heterozygous for rs8042861 (data not shown),
eliminating the possibility that absence of AI in the mi-
nority of the samples could be ascribed to a different
genotype at the MS-risk SNP.
To unravel whether the consistent AI observed for
IKZF3 could be attributed to the SNP most strongly as-
sociated to MS in this gene (rs12946510, which is in
high, but incomplete LD with rs907091 (r2 = 0.80, D’ =
0.90)), the samples were also analysed for double
Fig. 1 Consistent allelic imbalance is observed for rs907091 in IKZF3 and rs11609 in IQGAP1. ASE analyses for (a) rs11052877 in CD69, (b) rs907091
in IKZF3, and (c) rs11609 in IQGAP1 were performed in samples from whole blood from MS patients heterozygous for the indicated SNPs. Each
bar represents five replicate measurements. Data are presented as the normalized change in Ct between the two alleles (nΔCt). nΔCt values
above zero represents lower expression of the MS risk allele, whereas nΔCt values below zero represent higher expression of the MS risk allele.
Error bars represent the standard error of the mean. Unpaired Student’s t-tests were used to compare each column with the gDNA measurement,
P-values <0.05 were considered significant and are indicated with an asterisk. A > B = allele A expressed higher than B, A < B = allele A expressed
lower than B
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heterozygosity. We found that five of the samples were
homozygous for the MS top hit rs12946510. This indi-
cates that the observed AI is not driven by the genotype
of the MS top hit rs12946510 in whole blood.
To exclude that the observed AI for rs907091 and
rs11609 was limited to MS patients, we investigated ASE
also in a smaller set of samples from healthy controls.
We observed AI similar to the MS patients’ samples in-
dicating that the observed AI is independent of disease
status (Additional file 4: Figure S2).
Altogether, these data indicate that the studied SNPs
in IKZF3 and IQGAP1 are located in a cis-regulatory
element, or that these SNPs mark a functional cis-regu-
latory element that impacts the per-allele transcript
abundance in whole blood, independent of disease
status.
Samples from homozygous carriers of the risk allele at
rs11609 display higher IQGAP1 expression
To follow up the consistent AI of IKZF3 and IQGAP1
observed in heterozygous individuals, we selected the
samples that were homozygous for either allele of
rs907091 (IKZF3) and rs11609 (IQGAP1) to determine
whether the difference in allelic expression results in a
difference in overall gene expression. We did not ob-
serve significant differences in IKZF3 gene expression
between these two groups of homozygous for either the
risk allele or protective allele (Fig. 2a). However, for
IQGAP1, a significant genotype dependent expression
was identified with higher expression in samples homo-
zygous for the risk allele (Fig. 2b), in line with our ASE
analyses described above. To further investigate whether
higher IQGAP1 for the MS risk allele results in a higher
IQGAP1 protein level, we measured this expression by
Western blotting in lysates from peripheral blood mono-
nuclear cells from healthy individuals homozygous for
either the risk or protective rs11609 allele at IQGAP1.
Although we observe a slightly higher IQGAP1 expres-
sion in samples homozygous for the risk allele, this did
not reach significance (Additional file 5: Figure S3).
Discussion
Recent large-scale genotyping studies in MS have re-
vealed more than 110 genetic variants associated with
MS [4, 5], however, the functional impact of the majority
of these SNPs remains unknown and needs to be deter-
mined experimentally. To this end, we investigated the
ASE of three transcribed SNPs on MS susceptibility hap-
lotypes in whole blood of MS patients and show AI for
the SNPs rs907091 and rs11609, which are transcribed
in IKZF3 and IQGAP1, respectively. Furthermore, we
observed a significantly higher level of IQGAP1 gene ex-
pression for samples homozygous for the allele with a
relatively higher expression in the ASE measurements,
possibly indicating that the allelic imbalance persists be-
yond the relative expression of the alleles. Given this ob-
servation, a relative higher expression of IQGAP1 for
carriers of the minor allele might contribute to an in-
crease in MS susceptibility.
Allele-specific qPCR is a sensitive tool for evaluation
of cis-acting regulatory polymorphisms and can directly
detect differences in allelic output when assessed in het-
erozygous carriers. By examining the relative expression
levels of two alleles within the same biological sample,
variations introduced by the environment or differences
in physiological background of the individuals enrolled
in the study were minimized. AI measurements are rela-
tively robust for detecting and quantifying variations in
Fig. 2 Samples from homozygous carriers of the risk allele at rs11609 display higher IQGAP1 expression. Expression of IKZF3 and IQGAP1 relative
to 18S rRNA in samples from MS patients genotyped for (a) rs907091 in IKZF3 (TT (risk): n = 28; CC (protective): n = 44) and (b) rs11609 IQGAP1 (CC
(risk): n = 23; GG (protective): n = 36). Samples from individuals homozygous for the risk allele were compared with samples from individuals
homozygous for the protective allele with two-tailed Mann-Whitney U-test. P-values <0.05 were considered significant, only the significant p-value
is provided in the graph
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allelic expression. However, the AI observed in the MS
cases for IKZF3 and IQGAP1 was also observed in
healthy controls, indicating that MS itself does not im-
pact the AI of these genes.
It is important to note that the overall expression of a
gene can be influenced by multiple regulatory mecha-
nisms. Here we have a specific focus on those genetic
loci that were shown to have an association to MS. The
rs11609 SNP in IQGAP1 has been identified as an eQTL
for IQGAP1 in many tissues (for instance mammary, adi-
pose, thyroid, stomach and skin tissue), however not in
whole blood. In our study, we observe relatively higher
allelic expression of the MS-risk allele at rs11609, which
is consistent with higher overall gene expression of
IQGAP1 in samples homozygous for the risk allele. This
is similar to data from other tissues in the GTEx data
where rs11609 is reported as an eQTL with higher ex-
pression for carriers of the minor allele. Our data indi-
cate that also in whole blood, the haplotype on which
rs11609 resides has cis-regulatory properties affected by
genetic variation. We found double heterozygosity for all
samples except one for rs8042861 and rs11609 in
IQGAP1. The observed AI for rs11609 may originate
from different mechanisms of IQGAP1 gene regulation.
Interestingly, rs11609 is situated in an open chromatin
region (genome.ucsc.edu), making it a plausible candi-
date for influencing gene expression. However, there are
several SNPs in high LD with the MS associated
rs8042861 SNP that are within transcription factor bind-
ing sites (genome.ucsc.edu) and thereby might be the
causal SNP mediating the observed effect. Indeed, it has
been suggested that for most of the complex disease-
associated SNPs, the underlying SNP is predicted to be
located within the LD block of the associated SNP [14].
Further studies of genetic variation present in this region
of interest for functional properties are necessary to bet-
ter discern among these possibilities. The exact molecu-
lar mechanism of how higher IQGAP1 expression may
contribute to increased MS risk is unclear and warrants
more investigation. IQ Motif Containing GTPase Acti-
vating Protein 1 (IQGAP1) is a ubiquitously expressed
protein, belonging to the scaffolin-family, and has
emerged as a critical regulator of several signalling
pathways in a variety of cell types, including immune
cells, where it plays important roles for cytoskeleton-
mediated processes [22]. IQGAP1 has shown to be
instrumental for leukocyte chemotaxis and natural
killer (NK)-cell cytotoxicity [23, 24]. Higher IQGAP1
expression, as observed from MS risk loci, would lead
to aberrant leukocyte cell migration and NK cell ac-
tivity, and could thereby contribute to MS disease.
Furthermore, defects of the IQGAP1-interacting pro-
tein, Rap1b, result in multiple NK and B-cell dysfunc-
tions [25, 26], indicating that a change in IQGAP1
expression in those immune cells could also have an
impact for MS development. Although we observed
higher IQGAP1 protein expression in samples homo-
zygous for the risk allele, this did not reach statistical
significance. To reach 80 % power to detect a differ-
ence of this magnitude with this standard deviation, a
sample size of at least 43 in each group would be re-
quired (Additional file 6).
In agreement with the GTEx database (accessed
March 2016), we did not observe consistent allelic im-
balance for the CD69 gene, indicating that the SNP asso-
ciation to MS may not be attributable to cis-regulatory
properties in whole blood. Whether there are such cis-
regulatory properties for this SNP in more specialized
cell sub-types within the whole blood or other cells rele-
vant to MS remains to be investigated. However, in line
with our results, recent bioinformatic analyses indicated
that the genotype of the MS associated rs11052877 SNP
does not affect any transcription factor DNA binding
motifs [27].
The rs907091 SNP in IKZF3 has been shown to be an
eQTL influencing the expression or stability of the gene
transcript in lymphoblastoid cell lines [14, 15], but not
in whole blood (GTEx, accessed March 2016). The con-
sistent AI observed for rs907091 indicates that this
SNP potentially has eQTL properties in whole blood.
We did not observe differences of overall IKZF3 gene
expression between the homozygous carriers of the
minor and major allele, indicating that the eQTL
properties may be most pronounced in homogeneous
samples. Alternatively, our study may have a limited
sample size and therefore lack the power to detect
such differences in whole blood. Furthermore, the
blood samples used in this study are from an MS pa-
tient population at different disease stages and using
different treatments. This heterogeneity within the
sampled patients could contribute to the lack of dif-
ferential gene expression in samples sorted on differ-
ent genotypes.
It has previously been suggested that most disease var-
iants exert subtle and highly context-dependent effects
on gene regulation [14], therefore we cannot exclude
that using a comparable number of samples from spe-
cific immune cell subsets could detect IKZF3 expression
differences depending on the SNP genotype. The SNP
rs907091 is located in the 3’ untranslated region of the
IKZF3 gene encoding AIOLOS, an Ikaros transcription
factor involved in regulation of lymphocyte development
[28]. IKZF3 deficiency in mice mainly affects B cell func-
tion [29], giving rise to hyperactive immature B cell pre-
cursors [30, 31], and decreased peritoneal, marginal and
recirculating B cells [30, 32, 33]. An increase in IKZF3
expression in B cells might lead to aberrant B-cell re-
sponses that could play a role for MS development.
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Since there is a lack of complete double heterozygosity
between the AI SNP and the MS top-hit SNP
rs12946510 in IKZF3, the consistent AI observed for
rs907091 cannot be solely attributed to the genotype of
the MS-associated SNP. The mechanisms through which
the rs12946510 might have functional consequences for
MS development need further investigations. Moreover,
the probabilistic identification of causal SNPs fine map-
ping algorithm from the Broad Institute [14] indicates
that a large array of SNPs may be underlying the identi-
fied MS association signal, including rs907091, without a
clear indication for the actual functional SNP at this
locus. Therefore, the IKZF3 AI can be driven by multiple
SNPs without any of these having a probability above
20 % of being the true functional SNP. Previous experi-
mental studies have indicated that polymorphisms in
IKZF3 influence susceptibility for development of several
autoimmune disorders in addition to MS [14, 34–38].
Further investigations into how perturbation of the in-
vestigated genes in whole blood or in more specific cell
subtypes are needed to further elucidate how the SNPs
cis-regulation may contribute to MS risk.
Conclusions
This study showed a molecular mechanism, which might
contribute to the MS-association of two SNPs. We
identified differences in allelic output and/or overall
gene expression for rs907091 in IKZF3 and rs11609 in
IQGAP1, which are both in high LD with MS-associated
SNPs. Additional studies into the functional properties
of these SNPs and the impact on the protein expression
in specific cell types that are present in whole blood
may identify which cells drive the association of these
SNPs to MS development. Furthermore, since these
SNPs reside in large LD blocks that could harbour one
or more true functional variants, additional investiga-
tions to identify the true functional variations are
warranted.
Ethics (and consent to participate)
The Regional Committee for Medical and Health Re-
search Ethics South East, Norway, approved this study.




Availability of data and materials
The datasets supporting the conclusions of this article
are included in Additional file 7.
Additional files
Additional file 1: Table S1. PCR primers used to verify gene expression
of SNP-containing regions of the indicated genes in whole blood.
(PDF 133 kb)
Additional file 2: Figure S1. Assay sensitivity testing for allele-
specific expression with known ratios of alleles. Allele-specific qPCR
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P-values <0.05 are indicated with *. A > B = allele A expressed higher
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Additional file 5: Figure S3. IQGAP1 protein expression in peripheral
blood mononuclear cells from healthy controls. (a) Whole-cell lysates
from peripheral blood mononuclear cells from healthy controls
genotyped for rs11609 in IQGAP1 (CC (risk): n = 6; GG (protective):
n = 9) were immunoblotted with indicated antibodies. (b) Bands were
quantified and normalized with GAPDH as described in Materials and
Methods. The graph shows the mean with standard error of the
mean. A two- sided Mann-Whitney U-test was performed to compare
the groups. (TIF 1357 kb)
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